Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.66 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.60 |
| ▸ | TYR | P14679 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27724151 | 1.00 | HSD17B1 (0.66) | HSD17B1PTPN1TYRACHE | |
| SCHEMBL31237827 | 0.86 | PTPN1 (0.73) | HSD17B1PTPN1TYRACHE | |
| Phaseollidin SCHEMBL1545850 | 0.83 | PTPN1 (0.77) | HSD17B1PTPN1 | |
| Phaseollidin SCHEMBL29349654 | 0.83 | PTPN1 (0.77) | HSD17B1PTPN1 | |
| SCHEMBL23483682 | 0.80 | HSD17B1 (1.00) | HSD17B1PTPN1 | |
| SCHEMBL22948232 | 0.80 | HSD17B1 (1.00) | HSD17B1PTPN1 | |
| SCHEMBL30260469 | 0.80 | HSD17B1 (1.00) | HSD17B1PTPN1 | |
| Erybraedin A SCHEMBL29572007 | 0.78 | PTPN1 (0.76) | HSD17B1PTPN1TYR | |
| Erybraedin C SCHEMBL29572548 | 0.78 | PTPN1 (0.77) | HSD17B1PTPN1ACHE | |
| SCHEMBL29619822 | 0.78 | PTPN1 (0.67) | HSD17B1PTPN1TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414560-A1 | COMPOSITIONS AND METHODS FOR TREATING ECZEMA | General Nutraceutical Technology LLC | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414560-A1 | COMPOSITIONS AND METHODS FOR TREATING ECZEMA | ELANE, TSLP, EPX | HSD17B1 298/4885PTPN1 1394/4885TYR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.